← Eichor
Condition: Blasts More Than 5 Percent Of Bone Marrow Nucleated Cells Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Blasts More Than 5 Percent Of Bone Marrow Nucleated Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Phase 2 · 4 location(s) · William Shomali · NCT03801434CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Le
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03896269Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Phase 1/Phase 2 · 2 location(s) · Ohio State University Comprehensive Cancer Center · NCT04049539
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.